Scilex Holding Co (SCLX) Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - General
Scilex Holding Company NASDAQ:SCLX Healthcare · Drug Manufacturers - General
Mkt Cap $15.71M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 4
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
Datavault AI is party to an amended and restated non-binding LOI under which DataMEDS AI (NASDAQ: MEDS) would expand its exclusive license of Datavault AI's healthcare-related intellectual property, with DVLT receiving equity participation in DataMEDS plus royalties on use of its technologies.
The proposed transaction would also reunite the QOLPOM IP portfolio — biometric verification for drone and home drug delivery — from EOS Technology Holdings and Scilex, and have DataMEDS acquire a controlling interest in Tollo Health, targeting a Q4 2026 close.
Note that despite the input ticker, the release is issued by DataMEDS, not Datavault AI; DVLT's upside is contingent, and the LOI remains subject to definitive agreements, due diligence, a fairness opinion, and Nasdaq change-of-control review, with numerous related-party overlaps among the principals.
• 10d ago AI analysis › Press Release ⚠ 3
JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors
JP 3E Holdings, a proposed partner of Datavault AI, appointed three new directors including the CEO and CFO of Scilex Holding Company to strengthen its board.
The announcement reiterated the proposed $700 million strategic partnership with Datavault AI to develop the Strategic Materials Acquisition Platform (SMAP), which remains subject to financing and regulatory approvals.
DVLT is expected to contribute its RWA tokenization and blockchain-based settlement capabilities to the initiative.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company, signed a binding term sheet for a proposed $100 million strategic investment from iHolding Group LLP.
The agreement contemplates the purchase of 10 million newly issued shares at $10.00 per share, subject to due diligence and regulatory approvals, to fund the Phase 3 clinical program for SEMDEXA.
Proceeds will also support product development, commercialization, and working capital, strengthening the subsidiary's pipeline of non-opioid pain therapies.
• 3mo ago AI analysis › Press Release ⚠ 3
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
Scilex Holding Company announced that Dream Bowl I Meme Coin tokens, previously distributed to stockholders of both Scilex and Datavault AI, have commenced trading on the Biconomy Exchange.
The Biconomy Exchange serves over 10 million users across 180+ countries and reports an average daily trading volume of approximately $2.0 billion.
Scilex stated that the ability to trade the tokens may deliver liquidity to participating holders, noting that it currently holds approximately 180 million tokens following the prior distribution.
• 3mo ago AI analysis › Press Release ● Major
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Scilex Holding Company signed a binding term sheet with iHolding Group LLP for a proposed $100 million strategic investment in newly issued common stock at $15.00 per share.
The proposed transaction remains subject to due diligence, definitive agreements, and regulatory and shareholder approvals.
Net proceeds are intended to support strategic growth initiatives, including product development, commercialization, and potential acquisitions.
• 3mo ago AI analysis › Press Release
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
prnewswire.com • 4mo ago Press Release ⚠ 3
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Scilex Holding Company announced that Dream Bowl I Meme Coin tokens will list on Biconomy Exchange as early as June 23, 2026.
Biconomy serves over 10 million users with approximately $2.0 billion in average daily trading volume, aiming to provide liquidity for the token holders.
Shareholders of record as of April 30, 2026, were entitled to receive five Dream Bowl Tokens for each share of Scilex common stock held.
• 4mo ago AI analysis › Press Release ⚠ 2
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company confirmed the June 15, 2026 payment date for the dividend of Semnur Pharmaceuticals common stock to its shareholders.
The record date for the distribution is June 1, 2026, with Nasdaq setting the ex-dividend date for June 16, 2026.
Participating holders will receive one share of Semnur (OTC: SMNR) for every share of Scilex (NASDAQ: SCLX) held as of the record date.
• 4mo ago AI analysis › Press Release ⚠ 2
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company has set June 15, 2026, as the payment date for the previously announced stock dividend of Semnur Pharmaceuticals common stock.
Holders of record as of June 1, 2026, will receive one share of Semnur stock for every share of Scilex stock held.
Scilex currently owns approximately 186 million shares of Semnur and plans to distribute roughly 14 million of those shares to participating holders.
• 4mo ago AI analysis › Press Release ● Major ⚠ 3
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Scilex Holding Company announced its board approved a dividend of Semnur Pharmaceuticals common stock to SCLX shareholders.
Holders of record on June 1, 2026, will receive one share of Semnur (OTC: SMNR) for every share of Scilex held.
Scilex holds approximately 186 million Semnur shares and plans to distribute 10.7 million of them, retaining the majority stake.
• 5mo ago AI analysis › Press Release ● Critical
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Phoenix Asia Holdings (PHOE) entered into a definitive agreement to acquire ACEA Pharma from Scilex Holding Company (SCLX) for $1 billion in stock.
The transaction involves issuing 100 million Phoenix shares at $10.00 per share, with Scilex's subsidiary retaining approximately 82% ownership post-close.
Phoenix will be renamed ACEA Pharma, Inc. upon closing, shifting its focus from construction engineering to clinical-stage pharmaceuticals.
• 5mo ago AI analysis › Press Release ● Major
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026
globenewswire.com • 5mo ago Press Release ● Major
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
globenewswire.com • 6mo ago 
